We searched for published studies on the prevalence of erectile dysfunction (ED) in Asian populations, through Medline, PubMed, PsychInfo and scanned through reference lists. Data on prevalence rates were obtained and summarized for each Asian region, and were used to calculate pooled prevalence estimates using fixed and random effects models. As significant heterogeneity existed in certain age group categories, the random effects model was preferred. Twenty general population studies were identified. Six studies were eligible to be entered into the pooling of results, and provided 8653 subjects for analysis. The prevalence of ED increased with age. Pooled random effects age-specific prevalence rates were 15.1% (12.2-18.1), 29.6% (19.7-39.6), 40.6% (23.6-57.7), 54.3% (36.0-72.6) and 70.0% (62.3-77.7) for age groups 20-29, 30-39, 40-49, 50-59 and 60-69 years, respectively. Homogeneity of results in age groups 20-29 and 60-69 years suggested equally low and high prevalences of ED across Asian regions in these age groups, respectively. The overall reported prevalence in individual studies ranged from 2 to 81.8%. Prevalence rates and related information were summarized for each Asian region and for each study.
Introduction
Asia is the home to 60% (3.9 billion people) of the 6.4 billion people worldwide. 1 It has been estimated by Ayta et al. 2 that Asia has the largest number of men suffering from erectile dysfunction (ED) in 1995, 86.9 million men, compared to Europe (30.9), North America (11.9), Africa (11.5), South America (10.5) and Oceania (1.0). Projected into 2025 based on changes in population age structure, Asia will continue to have the largest number of 199.9 million men suffering from ED, reflecting a 130% growth, which will be the third fastest after Africa and South America. Like other age-related illnesses, ED will emerge as a public health problem as the world faces aging of its population. ED causes suffering on the individual level and has implications on the societal level. It is associated with age-related non-communicable chronic diseases such as diabetes, 3, 4 heart diseases 5 and hypertension, 6 as well as depression 7 that causes psychosocial suffering both to the individuals and to those around them. On the societal level, there will be an increasing need and demand for health-care budgets, medical facilities, and skills and training of medical personnel. The National Institute of Health Consensus Development Panel on Impotence defined ED as 'the consistent inability to sustain an erection sufficient for sexual performance.' 8 Rosen et al. 9 developed a screening instrument for ED that has been widely used and validated in more than 63 languages, the International Index of Erectile Function (IIEF-15), which was later abridged into a shorter version, the IIEF-5. 10 One of the largest study of ED in aging men, the Massachusetts Male Aging Study (MMAS), has evaluated the screening properties of a single screening question. 11 Other research methods include clinical diagnosis by clinicians, telephone interviews 12, 13 and measuring nocturnal penile tumescence.
Laumann et al. 14 noted that 'most epidemiological studies focused on North American and Western European populations, findings from other regions of the world are often based on smaller studies involving clinical series or other samples that are not broadly representative. ' Definitions and methodologies in ED research are varied, and have been regarded as a major source of variability in the prevalence estimates worldwide. Kubin et al. 15 in his review noted, 'comparisons of studies are, however, difficult because the terminology used to describe ED is inconsistentyconceptual confusion and difficulties in comparing published studies. ' Prins et al. 16 also noted, 'differences in definitions (derived from various questionnaires) are the main hindrance to comparing reported prevalencesyspecific data on age-specific and severity-specific prevalences are scarce, as is the information on comorbidity in these study populations. ' Few reviews have included many Asian studies, and hardly any reviewed Asia specifically. The need for Asian studies on ED should be self-evident after considering the disease burden that we face in Asia. Moreover, little attempt has been made to summarize the research findings from studies that have similar methodologies and definitions of ED. It can be argued that given the heterogeneity between studies, attempts to pool results will be futile, but it is the aim of this paper to find similarly conducted studies in Asia, and to pool their results together to have a larger sample size to make more reliable estimates of the prevalence.
The primary objective was to estimate the prevalence of ED in Asia. The secondary objectives were to provide a quick review on the published prevalence studies of ED in Asia, and to bring together scattered valuable research evidences accumulated so far in Asia.
Methods
We searched for studies documenting the prevalence of ED in Asian countries published between 1986 and April 2006. We did computer-based searches through Medline, PubMed, PsychInfo and other general internet search engines, searched for relevant journals and studies by hand, and scanned relevant reference lists. We used combinations of keywords related to the epidemiology (e.g. prevalence, frequency, epidemiology, incidence) and the disease entity (e.g. ED, impotence, sexual dysfunction). Non-English documents were noted and listed in this paper, but unless an English abstract was available, the contents were not included in this paper.
After elimination of irrelevant studies (Figure 1 ), the remaining studies were divided into two groups: (1) general population studies and (2) special population studies. General population studies referred to studies that were not clinical series, and they might or might not be representative of a geographical area or involved randomization. Special population studies referred to clinical series that were conducted on specific patient populations, which might or might not involve healthy control groups, and these healthy control groups if sufficiently large, comprehensive and representative 
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Assessment of eligibility
All general population studies that involved Asian populations and documented prevalence rates were included in this study. Eligible studies (Table 1) referred to those studies with similar methodologies and definitions of ED and therefore comparable in their results. The prevalence rates from eligible studies were pooled together by statistical methods. Given the scarcity of general population studies that used the same definitions of ED, we made some allowances by using the large representative control groups of special population studies, as well as allowing slightly different cutoff values for defining ED (e.g. a cutoff of 21 vs 20 in IIEF).
Assessment of quality of prevalence studies
As there were no established guidelines on evaluating prevalence studies, we adopted the quality assessment instrument from Prins et al. 16 The instrument has three parts, (1) internal validity, (2) external validity, and (3) informativity. All of the original assessment items in (1) and (2) were retained and expanded. To the original six items in the internal validity part, we added three items, (a), (g) and (i) ( Table 2 ). To the original six items in the external validity part, we splited two of the original items into four new items to reduce ambiguity and increase objectivity. The old item 'does the method to select and invite participants result in a study population that covers the complete population or a random sample?' was broken up into items (j) and (k). Item (k) in our new instrument was somewhat subjective, as the representativeness or generalizability is a matter of degree, rather than a yes/no question, but considering the different methodologies and definitions possible (e.g. does a telephone survey that involved randomization but had a low response rate qualify as representative? Or is a 5000 sample survey cross the whole country without randomization but covers sufficient number in each city representative?), we decided that a single subjective evaluative statement is better than many objective evaluative statements. Another old item, 'is the response rate 470%, or is the information on non-responders sufficient to make inference on the representativeness of the study population,' was split up into items (n) and (o). We added item (r) to our new instrument. For informativity part, we dropped two original items owing to their ambiguity and unanswerability, 'are the questions and answer possibilities stated?' and 'are the reported prevalence rates reproducible?' We added item (t) instead. Table 2 shows our expanded quality assessment instrument and Table 3 shows the results of quality appraisal.
Data extraction
Data were extracted according to a fixed protocol: year of study, methodology, definition of ED, response rate, patient population, randomization, sample size, age groups, age-specific prevalence, risk factors and outcome measures. The term 'response rate' was avoided as it referred to two things in the literature, (1) the participation rate (i.e. those who agreed to participate out of all those invited) or (2) the completion rate (i.e. completed questionnaires out of all questionnaires from those who participated or out of those eligible if eligibility applies) or both. Other studies only mentioned the number of eligible subjects out of all those contacted or participated (we will call this 'eligible proportion'). The terms 'participation rate,' 'completion rate' and 'eligible proportion' were used rather than 'response rate' in this paper. In studies where no numbers were given for age-specific prevalence, an estimation was made from the axes on the bar charts if they were given, and these cases were noted with a superscript b. Only statistically significant risk factors from the studies were listed, including unadjusted or adjusted risk factors.
Data synthesis
Short summaries were provided for each included study. Two methods were used to pool the prevalence figures from the six eligible studies: (1) fixed effects and (3) random effects models. Data from each age group of the eligible studies were used to calculate pooled age-specific prevalence estimates. The inverse-variance method was used for both Table 1 Eligibility criteria for inclusion into statistical pooling of results
Inclusion Exclusion
Similar definitions of ED were used Age-specific prevalences were given General population studies Special population studies with sufficiently large and representative healthy control subjects who were recruited from the larger general community fixed and random effects models, which were assessed by a test of homogeneity and the degrees of freedom were given. The 99% confidence interval (CI) was used for each estimate to allow for multiple comparisons. Age standardization was performed using the new world population standard. 17 All statistical calculations were performed by STATA version 7.0.
Results

Search for articles
Our initial search identified 219 articles, but only 34 documented the prevalence of ED in Asian populations. Eighteen of which were general population studies and 16 were special population studies. The distribution of the geographical regions that the 18 studies examined is shown in Table 4 . An overview of the general population studies is provided in 29 one used a question asking about erections after sexual stimulation 30 and two were indeterminate. 31, 32 The IIEF was most frequently used and so it became our definition of ED for statistical analysis. Of the five general population studies that used IIEF-5, one used a cutoff of 17, 19 two used 20 20, 21 External validity Study population (j) Was there randomization involved in the selection of study subjects? (k) Did the recruitment of study subjects make them representative of the target population or patient population they claim to study? Eligibility criteria (l) Was the age range specified? (m) Were inclusion and exclusion criteria specified? Response rate (n) Was the response rate a at least 70%? (o) Were information given about the non-responders that allow inference to be made on the representativeness of the study population? Description of study period (p) Was the study period specified? Description of study population (q) Were demographic characteristics of the study population given?
b Implications (r) Were implications of the results considered? (policy makers, clinicians, community) Informativity (s) Was the method of data collection (interview, questionnaire, additional measurement) adequately described? (t) Was the method of recruitment of study subjects adequately described?
a Treated as completion rate for quality appraisal. b Two or more of (i) age distribution, (ii) relevant comorbidity, (iii) lifestyle factors (e.g. smoking, alcohol), (iv) socioeconomic data (e.g.
income, educational level, marital status). 34 all being employees of 10 companies), (2) age-and severity-specific prevalences and (3) they used IIEF, and these were a rare combination that suited our study.
This provided us with 8653 subjects from the six eligible studies, of whom 976, 2124, 2905, 2186, 462 were in the age groups 20-29, 30-39, 40-49, 50-59 and 60-69 years, respectively. 
General population studies (ineligible)
Special population studies (use of control groups)
Total 4 2 14 1 21 
Only abstract was available in English
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Quality assessment
On average, eligible studies scored higher than ineligible studies across the three domains: 7.83 vs 5.71 for internal validity, 4.33 vs 3.71 for external validity and 1.67 vs 1.57 for informativity. No study scored positive for all internal or external validity criteria, although many scored positive for all the informativity criteria. The highest scoring paper was by Tan et al. 20 The cross-national studies 14, [24] [25] [26] 29, 30 generally scored lower than others according to the criteria in Table 3 : 5.5 for internal validity, 2.83 for external validity and 1.67 for informativity, particularly for items (c), (j), (k), (n), (o) and (r).
Those studies that used validated instruments (item (c)) generally did not specify the period (item (d)) that the instrument measured, whereas those that used unvalidated instruments generally did. Very few studies involved random sampling (item (j)) or gave information about the non-responders (item (o)). Not many studies specified inclusion or exclusion criteria (item (m)) or had a completion rate greater or equal to 70% (item (n)).
Ineligible studies that scored low could be because they were not intended to be prevalence studies but included prevalence figures. Also, if the information was not given for an item, it scored nothing.
Prevalence of ED from general population studies An overview of the overall prevalence rates for different Asian regions is provided in Table 8 . The reported prevalence of ED ranged from 2 to 81.8% across all studies.
Prevalence of ED in China
The reported prevalence of ED ranged from 19.5 to 28.3% in China from three general population studies. 18, 24, 27 Bai et al. 18 reported the overall Abbreviations: ED, erectile dysfunction; NS, not specified.
Erectile dysfunction in Asian populations JYW Cheng et al Table 6 General community studies that were included in the pooling of results for the estimation of age-specific prevalence in Asia. ED was commonly defined as some degree of ED using IIEF (arranged by region, author and then by year of publication) prevalence to be 28.3% in three major urban cities, and Lau et al. 27 reported the overall prevalence to be 19.5% in a rural area in China. Nicolosi et al. 24 reported from his cross-national study that the overall prevalence in China was 20%.
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Prevalence of ED in Hong Kong
Hong Kong's overall prevalence of ED ranged from 8 to 50%, reported from two local studies 13, 32 and two cross-national studies. 24, 29 Lau et al.'s 13 randomized telephone survey reported that the overall prevalence was only 9.6%. Chan et al. 32 did a survey at a government elderly service and reported the overall prevalence among elderly to be 34.1%. The crossnational GSSAB study by Nicolosi et al. 24 reported the prevalence to be 8%, whereas the cross-national Asian Survey of Aging Males (ASAM) study by Li et al. 29 reported it to be 50%.
Prevalence of ED in Indonesia
Only one study, the GSSAB study by Nicolosi et al., 24 reported the overall prevalence in Indonesia and it was 11%.
Prevalence of ED in Japan
The reported overall prevalence ranged from 13 to 81.1%.
Japan has the largest number of general population studies for ED. Six out of the 10 studies used either IIEF-5 or IIEF-15, but only two used the same cutoff, which was the original cutoff defined by Rosen et al. 9 The studies mentioned in the next paragraph used either IIEF-5 or IIEF-15.
The two special population studies by Naya et al. 33, 34 included two large populations of healthy controls and the overall prevalence rates in these groups were 36.1 and 43.3%. Terai et al.'s 21 study had the largest sample size (among the Japanese studies) that provided age-specific prevalence, and the overall prevalence rate was 69.4%. The study that had the largest sample size (among the Japanese studies) but without age-specific prevalence was Sasayama et al.'s, 22 and the overall prevalence was 81.1%. Marumo et al. 23 and Sugimori et al. 7 reported the overall prevalence to be 13.2 and 15.7%, respectively.
The two GSSAB studies 24, 26 that included Japan reported the overall prevalence to be 13 24 and 34.5%. 26 
Prevalence of ED in Malaysia
All three studies were cross-national studies. Li et al.'s 29 ASAM study reported an overall prevalence of 59%. Nicolosi et al.'s 24, 26 GSSAB studies reported the prevalence to be 22.4 and 28%. The overall range was 22.4-59%.
Prevalence of ED in Philippines
Only two cross-national studies included data for Philippines. The ASAM 29 study reported an overall prevalence of 65%, and the GSSAB 24 study reported it to be 33%. The overall range was between 33 and 65%.
Prevalence of ED in Singapore
The range of overall prevalence was from 2 to 53%, reported from one local study 20 and two crossnational studies. 24, 29 The randomized community study by Tan et al. 20 reported an overall prevalence of 51.3%. The ASAM 29 study reported the overall prevalence to be 53% and the GSSAB 24 study reported it to be 2%.
Prevalence of ED in South Korea
The overall prevalence ranged from 18 to 36.6%, reported from one local study 19 and one crossnational study. 29 Cho et al.'s 19 survey of the primary care sector reported the overall prevalence to be 36.6%. The GSSAB 29 study reported the overall prevalence to be 18%.
Prevalence of ED in Taiwan
The overall prevalence ranged from 9 to 17.7%, reported from one local study 12 and one crossnational study. 29 Chen et al.'s 12 randomized telephone survey reported the overall prevalence to be 17.7%. The GSSAB 29 study reported the overall prevalence to be 9%. 
Prevalence of ED in Thailand
Thailand has one local study 28 and two cross-national studies 24, 29 on its ED prevalence. The reported overall prevalence ranged from 29 to 65%. Kongkanand et al.'s 28 survey across the country reported an overall prevalence of 37.5%. The ASAM 29 study reported the overall prevalence to be 65%. The GSSAB 24 study reported the overall prevalence to be 29%.
Pooled prevalence of ED from eligible studies ( Table 9 , Figures 2-8 ) We included two, four, six, six and three studies for the estimation of age-specific prevalences in the age groups 20-29, 30-39, 40-49, 50-59 and 60-69 years, respectively, and as different studies included different age groups, we based our analysis on whatever data were available in the eligible studies.
The age-standardized prevalence was 36.8%. The weighted (based on the population sizes of the studies included) fixed-effects overall prevalence was 38.2% (0.369, 0.394), and the random effects estimate was 42.4% (0.200, 0.647).
The prevalence of ED increased with age. Weighted pooled fixed-effects age-specific prevalence rates were 15 Tests of heterogeneity were highly significant (Po0.001) for the age groups 30-39, 40-49 and 50-59 years, and hence the fixed-effects model was significantly different from the random effects model and the random effects model was preferred for these age groups. Tests of heterogeneity were not significant for age groups 20-29 and 60-69 years, and the fixed-effects model was not likely to be different from the random effects model and both models could be used for these age groups. Table 9 shows the age-specific prevalence rates from each eligible study and the relevant raw data for computation. It also shows the results of the weighted fixed and random effects models, and their tests of heterogeneity.
Forest plots for each age group are shown in Figures 2-6 , and the forest plot for the overall prevalence is shown in Figure 7 . Line graph is shown in Figure 8 illustrating the data from Table 9 graphically.
Discussion
To our knowledge, this is the first review paper to derive pooled age-specific prevalence estimates for Abbreviations: CI, confidence interval; d.f., degrees of freedom.
Note: The figures in italic were not used in the calculation of the pooled estimates because these were in 'open-ended' age groups where the distribution of subjects within these groups could not be determined, and if they were predominantly on the younger end, it would underestimate the prevalence in that age group, likewise if they congregated on the older end, it would overestimate the prevalence.
Erectile dysfunction in Asian populations JYW Cheng et al ED, and the first review paper on ED prevalence in Asian populations. We have shown that it was possible for research in this field to be carried forward by bypassing the impossible comparison step between differently conducted studies and pooling together what was comparable to derive a summary estimate. The fixed-effects model assumed that a 'true prevalence' existed in each study, Erectile dysfunction in Asian populations JYW Cheng et al whereas the random effects model assumed that the prevalences for individual studies varied around some overall average. As ED is subject to numerous influences, and especially as it is common belief in the ED scientific community that ED prevalences vary between geographical regions, the random effects model is most useful in the context of ED, as it was assumed in this study that there is some true prevalence of ED using the same method of assessment within the same geographical region, with IIEF and Asia as our common instrument and geographical unit. Age has been shown to be one of the most, if not the most, powerful and consistent predictor of ED. Given the differences in the age distribution of the study populations in different studies, and hence the differences in age-related ED, it was almost impossible to compare the prevalence rates of ED between different studies. It is important therefore to take age into account when comparing prevalence of ED across different studies, but it is often difficult and therefore neglected. In this study, we allowed the combination of data between studies to be made by removing the effect of age on ED by using agespecific prevalence rates.
The 99% CI was used (and not 95%) because given the heterogeneity between studies, we wanted to increase the probability that the true value can be found within the CI upon repeated testing. The 99% CI was widest for the random effects model, not surprisingly as it assumed different prevalences to exist but to vary within certain average. The upper and lower 99% CI tapered toward both ends of the age distribution, and the tests of heterogeneity were not significant for the age groups 20-29 and 60-69 years, suggesting the existence of some common prevalence of ED across geographical regions in Asia in these age groups. This might reflect the biological constraints that age brings to erectile function at late life, and also reflect the general good sexual functioning of young people in their 20s, that is, the prevalences between places vary around some biologically determined norm. Laumann et al.
14 also noted that, 'in all regionsymen aged 60-80 y are significantly more likely to report erectile difficulties than those aged 40-49 y (OR from 2.7 to 6.9).' People in between tended to have more variations in prevalence, and were likely to be subject to numerous factors including local disease patterns (biological, psychological), local average income, local health accessibility and health seeking behavior (and maintenance of health), and other factors that can influence ED. This was reflected in the forest plots by the overlap (or lack of) of the 99% CI of individual studies, and was most obvious for the 60-69 years age group, less so for 20-29 years age group, but less for the age groups in between. This suggested that in the 60-69 years age group, there was indeed a true prevalence for Asian populations, at least for China, Japan and Singapore.
The results of this study highlighted the need for a common ED assessment instrument, particularly in cross-national studies. The famous MMAS and GSSAB studies demonstrated just how incompatible results could be. MMAS did not provide age-specific prevalence until a paper was published as late as 1997 from the baseline data and before that used age-related probability obtained by discriminant analysis that was unique in the ED literature. GSSAB studies used two sequential questions and one study used just one question, and hardly any Asian studies used the same questions for their studies. Table 8 shows the overall prevalence in different regions. It was curious to note that the cross-national studies [24] [25] [26] 29 contributed to many of the extreme figures in this table, with the GSSAB studies contributing to 12 out of the 13 lower limits, and the ASAM study contributing to five of the 13 upper limits. This could be due to (1) the lack of local research papers and only the cross-national studies provided the information, or (2) that the ED prevalence figures were genuinely higher or lower than average and this could mean problems with the internal (e.g. small non-random samples from each country, and different methodologies for collecting data in different countries) or external validity (e.g. despite robust cross-national comparisons within the framework of the study, the results cannot be compared with the results of other studies) of the cross-national studies. Reason (1) appears to be true for five regions, as only two papers (i.e. lack of papers) were found for these regions. Only one out 
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JYW Cheng et al of five of the regions with ASAM being upper limit has only two papers, suggesting that reason (2) appears to apply to ASAM. Hence, seven out of the 13 lower limits and four of the 13 upper limits could not be explained by the lack of local research papers, and seems to suggest problems of external validity for the cross-national studies in Asian countries. Hence, at present, IIEF remains the instrument of choice for most Asian studies on ED. This study has several limitations. The reviewed studies covered only a handful of Asian countries, mainly in East Asia and Southeast Asia. Studies related to other Asian countries could be missed, as they were not indexed in the databases that we searched or they could be written in a native language and published in a local journal. Economical (e.g. lack of funding or research information) or sociocultural (e.g. taboo, natives not willing to participate) constraints might have also prevented ED studies from being undertaken in these countries. Another limitation is the comparison between studies. The use of the control group data of special population studies might not be ideal, as it did not involve randomized recruitment of subjects (but only a few studies had randomization) and might not be representative of the regions they studied. The toleration of studies using slightly different cutoffs might have affected the summary statistics because the definitions of ED are different, and the comparison of results obtained through validated versions of IIEF in different languages might be problematic because no one has validated the comparison between validated IIEF in different local languages. The internal validity scores for eligible studies were high, but external validity scores were low for three of the six studies (Table 3) .
Future ED studies can contribute more to the scientific community by (1) providing age-specific and severity-specific prevalence, and the population data for each age group and by (2) adopting the most widely used ED assessment instrument and their cutoff criteria to allow international comparisons (use newer ones only when evidence suggests better properties).
